Last reviewed · How we verify
LAmB B
At a glance
| Generic name | LAmB B |
|---|---|
| Sponsor | University of Minnesota |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) (PHASE3)
- Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) (PHASE3)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- Percutaneous Wound Sampling With Analysis in Blood Culture (PERKA-B) Method (NA)
- Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) (PHASE3)
- L-AmB_ Retrospective mUlticenter Study on Mycosis prOphylaxis
- Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole (PHASE3)
- Amphotericin Versus Posaconazole for Pulmonary Mucormycosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAmB B CI brief — competitive landscape report
- LAmB B updates RSS · CI watch RSS
- University of Minnesota portfolio CI